Table of Content

Chapter 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
Chapter 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
Chapter 4: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market Size and Forecast, By Drug class
4.2. Monoclonal antibodies
4.3. Intravenous immunoglobulin
4.4. Others
Chapter 5: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market Size and Forecast, By Age group
5.2. Below 55 years
5.3. Above 55 years
Chapter 6: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market Size and Forecast, By Distribution channel
6.2. Hospital pharmacies
6.3. Drug store and retail pharmacies
6.4. Online providers
Chapter 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
Chapter 8: COMPANY PROFILES
8.1. GlaxoSmithKline plc.
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Pfizer, Inc.
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Johnson & Johnson
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Novartis AG
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Sanofi
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. F. Hoffmann-La Roche Ltd.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. AbbVie Inc.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Mylan N.V.
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Teva Pharmaceutical Industries Ltd.
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Biogen Inc.
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments



List of Figures

LIST OF FIGURES
FIGURE 01. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 10. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET,BY DRUG CLASS, 2022 ($MILLION)
FIGURE 11. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET,BY AGE GROUP, 2022 ($MILLION)
FIGURE 12. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022*?($MILLION)
FIGURE 21. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. PFIZER, INC.: NET SALES, 2020-2022*?($MILLION)
FIGURE 24. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. PFIZER, INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. JOHNSON & JOHNSON: NET SALES, 2020-2022*?($MILLION)
FIGURE 27. JOHNSON & JOHNSON: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. JOHNSON & JOHNSON: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. NOVARTIS AG: NET SALES, 2020-2022*?($MILLION)
FIGURE 30. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. NOVARTIS AG: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. SANOFI: NET SALES, 2020-2022*?($MILLION)
FIGURE 33. SANOFI: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. SANOFI: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022*?($MILLION)
FIGURE 36. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. ABBVIE INC.: NET SALES, 2020-2022*?($MILLION)
FIGURE 39. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. ABBVIE INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. MYLAN N.V.: NET SALES, 2020-2022*?($MILLION)
FIGURE 42. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. MYLAN N.V.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022*?($MILLION)
FIGURE 45. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. BIOGEN INC.: NET SALES, 2020-2022*?($MILLION)
FIGURE 48. BIOGEN INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. BIOGEN INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

List of Tables

LIST OF TABLES
TABLE 01. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 03. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 04. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
TABLE 05. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 06. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 07. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 08. GLAXOSMITHKLINE PLC.: KEY STRATERGIES
TABLE 09. PFIZER, INC.: KEY EXECUTIVES
TABLE 10. PFIZER, INC.: COMPANY SNAPSHOT
TABLE 11. PFIZER, INC.: OPERATING SEGMENTS
TABLE 12. PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 13. PFIZER, INC.: KEY STRATERGIES
TABLE 14. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 15. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 16. JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 17. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 18. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 19. NOVARTIS AG: KEY EXECUTIVES
TABLE 20. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 21. NOVARTIS AG: OPERATING SEGMENTS
TABLE 22. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 23. NOVARTIS AG: KEY STRATERGIES
TABLE 24. SANOFI: KEY EXECUTIVES
TABLE 25. SANOFI: COMPANY SNAPSHOT
TABLE 26. SANOFI: OPERATING SEGMENTS
TABLE 27. SANOFI: PRODUCT PORTFOLIO
TABLE 28. SANOFI: KEY STRATERGIES
TABLE 29. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 30. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 31. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
TABLE 32. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 33. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 34. ABBVIE INC.: KEY EXECUTIVES
TABLE 35. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 36. ABBVIE INC.: OPERATING SEGMENTS
TABLE 37. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 38. ABBVIE INC.: KEY STRATERGIES
TABLE 39. MYLAN N.V.: KEY EXECUTIVES
TABLE 40. MYLAN N.V.: COMPANY SNAPSHOT
TABLE 41. MYLAN N.V.: OPERATING SEGMENTS
TABLE 42. MYLAN N.V.: PRODUCT PORTFOLIO
TABLE 43. MYLAN N.V.: KEY STRATERGIES
TABLE 44. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 45. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 46. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 47. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 49. BIOGEN INC.: KEY EXECUTIVES
TABLE 50. BIOGEN INC.: COMPANY SNAPSHOT
TABLE 51. BIOGEN INC.: OPERATING SEGMENTS
TABLE 52. BIOGEN INC.: PRODUCT PORTFOLIO
TABLE 53. BIOGEN INC.: KEY STRATERGIES